I counter on that. Maria can easily bring profit to the company at the expense of company growth i.e. stop every cash burning activity, sell the product and do not spend more than what she can sell/earn.
Is this the approach we are after? Hell no.
What I see, is the failure on selling the science, Because of this failure, we have to suffer linear trajectory growth. And Maria will started to find it more difficult when the business getting expanded. She is inexperience, she has to experience it, before she knew what is going to be happen next. Mediocre CEO, maybe Dennis Eck can do a better job.
Makes people know fgf5, not evolis joju or lexilis. Selling shampoo, no need to be creative, but selling fgf5, have to be creative. Textbook never teach how to sell a science, nor does her MBA taught her how to do it. Hopefully her MBA taught her how to jump out from her comfort zone and brainstorm on this issue.
- Forums
- ASX - By Stock
- AN1
- Ann: Cellmid's Evolis Registered in European Union (EU)
Ann: Cellmid's Evolis Registered in European Union (EU), page-41
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online